Radiotherapy Combined with Pyrotinib Plus Capecitabine in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases: A Single-Arm, Exploratory Trial

被引：0
|
作者：
Wang, J. [1 ]
Wang, P. [2 ]
You, J. [2 ]
Wang, X. [3 ]
Hou, H. [2 ]
Zhang, B. [2 ]
Chai, Y. [2 ]
Cao, Y. [2 ]
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2625
引用
收藏
页码：E283 / E284
页数：2
相关论文
共 50 条
  • [31] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Min Yan
    Limin Niu
    Huimin Lv
    Mengwei Zhang
    Jing Wang
    Zhenzhen Liu
    Xiuchun Chen
    Zhenduo Lu
    Chongjian Zhang
    Huiai Zeng
    Shengnan Zhao
    Yajing Feng
    Huihui Sun
    Huajun Li
    Nature Communications, 14
  • [32] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Yan, Min
    Niu, Limin
    Lv, Huimin
    Zhang, Mengwei
    Wang, Jing
    Liu, Zhenzhen
    Chen, Xiuchun
    Lu, Zhenduo
    Zhang, Chongjian
    Zeng, Huiai
    Zhao, Shengnan
    Feng, Yajing
    Sun, Huihui
    Li, Huajun
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [33] Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
    Lin, Nancy U.
    Carey, Lisa A.
    Liu, Minetta C.
    Younger, Jerry
    Come, Steven E.
    Ewend, Matthew
    Harris, Gordon J.
    Bullitt, Elizabeth
    Van den Abbeele, Annick D.
    Henson, John W.
    Li, Xiaochun
    Gelman, Rebecca
    Burstein, Harold J.
    Kasparian, Elizabeth
    Kirsch, David G.
    Crawford, Ann
    Hochberg, Fred
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 1993 - 1999
  • [34] Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial
    Ye, Guolin
    Chen, Peixian
    Liu, Xiangwei
    He, Tiancheng
    Pivot, Xavier
    Pan, Ruilin
    Zhou, Dan
    Zhu, Lewei
    Zhang, Kun
    Li, Wei
    Yang, Shuqing
    Lin, Jiawei
    Cai, Gengxi
    Huang, Huiqi
    GLAND SURGERY, 2024, 13 (03) : 374 - 382
  • [35] Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer
    Eberst, Lauriane
    Bailleux, Caroline
    Bachelot, Thomas
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (06) : 555 - 560
  • [36] Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient
    Freedman, Rachel A.
    Muss, Hyman B.
    JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (01) : 2 - 7
  • [37] Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases
    Wang, Congcong
    Xiang, Jinyu
    Zhang, Qingyu
    Li, Jing
    Liu, Yanqing
    Liu, Jiannan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 909 - 917
  • [38] Management of Human Epidermal Growth Factor Receptor-2(HER2) Positive Breast Cancer Patients at University Hospitals of Leicester
    Kaushik, M.
    Rattay, T.
    Shokuhi, S.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S94 - S94
  • [39] The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)
    Duan, Fangfang
    Zhong, Muyi
    Ma, Yuyu
    Song, Chenge
    Zhang, Lehong
    Lin, Ying
    Wu, Zhiyong
    Zhang, Yuanqi
    Huang, Jiajia
    Xu, Fei
    Shi, Yanxia
    Wang, Shusen
    Yuan, Zhongyu
    Xia, Wen
    Bi, Xiwen
    BMC CANCER, 2022, 22 (01)
  • [40] The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)
    Fangfang Duan
    Muyi Zhong
    Yuyu Ma
    Chenge Song
    Lehong Zhang
    Ying Lin
    Zhiyong Wu
    Yuanqi Zhang
    Jiajia Huang
    Fei Xu
    Yanxia Shi
    Shusen Wang
    Zhongyu Yuan
    Wen Xia
    Xiwen Bi
    BMC Cancer, 22
12345